Advertisement
Home Tags Cancer: Misc.

Tag: Cancer: Misc.

Comprehensive computed tomography screening in addition to a limited occult-cancer screening offers no benefit over limited screening alone for patients with a first unprovoked venous thromboembolism. The finding was published online June 22 in the New England Journal of Medicine to coincide with the International Society on Thrombosis and Haemostasis 2015 Congress

No Clinical Benefit Found for Occult Cancer CT Screening in VTE

0
Prevalence of occult cancer low among patients with first unprovoked venous thromboembolism
For cancer care workers

One-Day Workshop Ups Stress Recovery for Cancer Care Workers

0
Findings show beneficial effects for radiation therapists and oncology nurses
HIV-infected patients with cancer have increased cancer-specific mortality

Cancer-Specific Mortality Up in HIV-Infected Cancer Patients

0
HIV linked to increased risk for colorectum, lung, skin, and breast cancer independent of treatment
About half of U.S. deaths caused by certain cancers -- including lung

Half of Cancer Deaths Due to Past, Current Smoking

0
Eighty percent of lung cancer deaths linked to smoking, researchers say
For long-term childhood cancer survivors

Cardiac Dysfunction in Childhood Cancer Survivors Examined

0
Long-term survivors have greater prevalence of abnormal global longitudinal strain, diastolic function
Scanning maternal plasma cell-free DNA as part of routine noninvasive prenatal testing may also enable presymptomatic detection of maternal tumors

Cancers ID’d With Maternal Plasma Cell-Free DNA Sequencing

0
Sequencing as part of routine noninvasive prenatal testing enables presymptomatic ID of tumors

American Society of Clinical Oncology, May 29 – June 2

0
The 51st Annual Meeting of the American Society of Clinical Oncology The annual meeting of the American Society of Clinical Oncology (ASCO) was...
Mortality rates among five-year childhood cancer survivors 15 years after diagnosis have been halved since the 1970s -- falling from 12.4 to 6 percent

ASCO: Longevity Improving for Childhood Cancer Survivors

0
Fewer die of 'late effects' from radiation, chemotherapy
The drug elotuzumab reduces the risk of cancer progression and mortality by 30 percent when combined with the standard two-drug therapy for multiple myeloma

ASCO: Elotuzumab Shows Benefit in Multiple Myeloma

0
Survival gains when elotuzumab was added to treatment

May 2015 Briefing – Hematology & Oncology

0
Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for May 2015. This roundup includes...